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Abstract
Background: Pain is often inadequately evaluated and treated in sub-Saharan Africa (SSA).
Objective: We sought to assess pain levels and pain treatment in 400 hospitalized patients at a national referral
hospital in western Kenya, and to identify factors associated with pain and pain treatment.
Design: Using face-validated Kiswahili versions of two single-item pain assessment tools, the Numerical Rating
Scale (NRS) and the Faces Pain Scale–Revised (FPS-R), we determined patients’ pain levels. Additional data
collected included patient demographics, prescribed analgesics, and administered analgesics. We calculated
mean pain ratings and pain management index (PMI) scores.
Results: Averaged between the NRS and FPS-R, 80.5% of patients endorsed a nonzero level of pain and 30% of
patients reported moderate to severe pain. Older patients, patients with HIV, and cancer patients had higher
pain ratings. Sixty-six percent of patients had been prescribed analgesics at some point during their hospitali-
zation, the majority of which were nonopioids. A majority of patients (66%) had undertreated pain (negative
scores on the PMI).
Conclusion: This study shows that hospitalized patients in Kenya are experiencing pain and that this pain is
often undertreated.
Introduction
The World Health Organization pain ladder pro-motes a stepwise approach to pain management to min-
imize inadequate analgesia.1 For mild pain it recommends
that patients receive acetaminophen or a nonsteroidal anti-
inflammatory drug. If the pain persists or if the patient has
moderate pain, a weak opioid should be used. For severe pain
or pain inadequately treated with weak opioids, a strong
opioid should be prescribed.
However, patients around the world suffer from the global
inequality of pain relief. In 2006, developed nations consumed
most of the world’s opioid supply. The global mean of mor-
phine consumption was 5.98 mg per person per year, while
the regional mean for Africa was only 0.33 mg.2 In 2008, 20
sub-Saharan African (SSA) countries reported no morphine
use at all.3
In addition to disparities of pain relief, there is a dearth of
rigorous research on pain management in SSA, especially
research that can be translated into clinical practice.4 Pain
assessment and treatment are essential parts of caring for
patients, but in SSA there are many barriers to adequate pain
control. These include a deficiency of culturally acceptable
and validated pain assessment tools; lack of pain manage-
ment education for clinicians; unavailability of opioids due to
national drug policies and unreliable supply chains; under-
prescribing of pain medication; and difficulty in accessing
health care.2,5–8
These factors contribute to a high burden of pain in SSA. In
cancer patients receiving inpatient or outpatient care in South
Africa, 35.7% reported cancer-related pain.9 Cancer patients
in Uganda and South Africa had a pain prevalence of 87.5% in
spite of their participation in palliative care services.10 Simi-
larly, two-thirds of hospice patients in Uganda had
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experienced extended periods of severe pain before their pain
was adequately treated.11 Prior work in Kenya has also shown
that patients often die in pain.12,13 Beyond actively dying
patients and those with fatal malignancies, patients with
chronic conditions also experience untreated pain—studies
have found the prevalence of pain to be 59% to 98% among
HIV/AIDS patients in South Africa, Uganda, and Kenya.14–17
Research on the correlates of pain in SSA has found that in
HIV patients, pain has been associated with increasing age,
female gender, not being on antiretroviral therapy, number of
symptoms, advanced disease, number of medical comorbid-
ities, and reduced functional performance scores.18–20 These
studies are specific to ambulatory HIV/AIDS patients, and to
date no research has been conducted to determine the burden
of pain in a mixed inpatient hospital setting in SSA.
The pain experienced by pediatric patients in SSA is espe-
cially neglected, with very limited data on this subject.21,22
Pediatric patients face exclusion from adult palliative care
services and reluctance from clinicians to treat children with
opioids due to the belief that using morphine amounts to
‘‘giving up.’’21
One challenge faced in clinical practice in SSA is the limited
number of fully validated pain assessment tools. Our group
recently established the face validity of Kiswahili versions of
two single-item pain scales, the Faces Pain Scale–Revised
(FPS-R) and the Numerical Rating Scale (NRS), in both adults
and children through rigorous cognitive interviewing in
Kenya.23 While only the face validity has been formally es-
tablished, the NRS and a variation of the FPS-R are re-
commended for national use by the Kenya Hospices and
Palliative Care Association.24 In this study we use these scales
to assess the prevalence and intensity of pain in a population
of hospitalized patients in western Kenya, and describe the
correlates of pain, pain treatment, and undermedication as
determined by the Pain Management Index (PMI). We also
sought to establish the convergent validity of these two scales
as further evidence of their applicability in our setting.
Methods
Setting
Moi Teaching and Referral Hospital (MTRH) is a national
referral hospital in Eldoret, Kenya serving western Kenya,
with a catchment population of about 11.2 million. The hos-
pital includes full outpatient services and a 500 inpatient bed
capacity, although this bed count underestimates the inpa-
tient population, as patients frequently share beds on the
wards. The adult medical, pediatric, and surgical wards house
265 of the 500 beds. Patients are admitted for a variety of acute
and chronic medical illnesses, including tuberculosis, malaria,
HIV, trauma, and cancer. Under the auspices of a cancer treat-
ment program developed through the President’s Emergency
Plan for AIDS Relief (PEPFAR)-supported Academic Model
Providing Access to Healthcare (AMPATH) program, a pallia-
tive care team was formed in 2009 to address the needs of cancer
patients. However, in the interim three years, this program has
expanded to offer symptom management and psychosocial
support to patients on the wards regardless of diagnosis.
This study was approved by the institutional research and
ethics committee of Moi University School of Medicine and by
the institutional review board of Indiana University School of
Medicine.
Population
From March to July 2011, hospitalized patients ages five
years and older with the ability to speak Kiswahili or English
and with the mental and physical capacity to give informed
assent (for pediatric patients ages 14 and under) or consent
(for adult patients and for parents or guardians of pediatric
patients) were asked to participate in this study. Patients were
randomly selected using an online random number generator
corresponding to inpatient bed numbers on the adult medical,
adult surgical, and pediatric wards. To ensure the inclusion of
an adequate number of oncology patients we employed a
different sampling strategy for these patients. Adult oncology
patients are housed throughout the hospital, with about 15
adult and 5 pediatric oncology patients active on the oncology
service at any given time. Thus, we recruited any oncology
patients listed on the oncology service at the beginning of the
study and continued to recruit any additional oncology pa-
tients admitted throughout the course of the study to ensure
adequate sampling of that population. Verbal, witnessed in-
formed consent and/or assent using a standard consent or
assent form was obtained from all participants and their
parents or guardians, if applicable.
Pain assessment and data collection
The NRS and FPS-R are two single-item pain assessment
tools. The NRS has been found to have high sensitivity and
ease of administration compared to similar but nonnumerical
scales such as the Verbal Rating Scale and the Visual Analo-
gue Scale.11,25–28 It is scored from 0 to 10, with 0 being no pain
and 10 being the worst pain the patient can imagine. The FPS-R
was developed for use in pediatric populations but has been
validated in all age ranges, showing the best psychometric
properties in comparison to other faces pain scales.29–34 It
consists of six faces in increasing levels of distress and can be
scored on the same 0 to 10 scale as the NRS. Our group re-
cently established the face validity of Kiswahili versions of the
NRS and FPS-R in this population through rigorous cognitive
interviewing.23 These two pain scales specifically assess a
patient’s current pain.
The Kiswahili versions of the NRS and FPS-R were adminis-
tered one time to each child or adult participant to assess current
pain at any point after hospital admission. The pain scales were
administeredbymembersoftheMTRHpalliativecareteamwho
had been trained in pain assessment and research methodology.
Demographic and clinical information for each patient were
subsequently gathered through review of the patient’s paper
hospital record. These data included age, gender, working di-
agnosis, chronic medical problems, whether any pain medica-
tions had been prescribed, and times of pain medication
administration within the past 72 hours, if any. The categoriza-
tion of cancer or suspected cancer was assigned based on a pa-
tient’s working diagnosis as recorded in the medical chart.
Data analysis
Descriptive statistics for patient characteristics were de-
scribed as means or medians for continuous variables (e.g.,
age) and as proportions for categorical variables (e.g., gen-
der). Prescribed analgesics were compared with administered
analgesics to determine whether all pain medicines were
given as prescribed.
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Table 1. Pain Management Index Scoring
PMI pain score 0 (none) 1 (mild pain) 2 (moderate pain) 3 (severe pain)
PMI analgesic score
0 (no pain medicine) 0 - 1 - 2 - 3
1 (nonopioid) 1 0 - 1 - 2
2 (weak opioid) 2 1 0 - 1
3 (strong opioid) 3 2 1 0
The Pain Management Index (PMI) was calculated by subtracting the patient’s Pain Score from the patient’s Analgesic Score. The PMI Pain
Score was derived from the patient’s response to the NRS or FPS-R, with a PMI Pain Score of 0 corresponding to a score of 0 on the NRS or the
first face (from left) of the FPS-R. A PMI Pain Score of 1 corresponded to a score of 1 to 4 on the NRS or the second or third face of the FPS-R.
A PMI Pain Score of 2 corresponded to a score of 5 or 6 on the NRS or the fourth face on the FPS-R. A PMI Pain Score of 3 corresponded to a
score of 7 to 10 on the NRS or the fifth or sixth face on the FPS-R. The PMI Analgesic Score was determined based on the strongest pain
medicine the patient had received within the last six hours. Negative scores indicate undertreatment of pain.
NRS, Numerical Rating Scale; FPS-R, Faces Pain Scale-Revised.
Table 2. Demographics, Pain Ratings, and Pain Management Index Scores
Demographic
variable Number (%)
Mean
NRS
Median
NRS p-value
Mean
FPS-R
Median
FPS-R p-value
% Negative
NRS PMI p-value
% Negative
FPS-R PMI p-value
Age (in years)
Mean 29.7
Range 5–88
Gender
Male 213 (53) 3.56 3 0.822 3.70 2 0.608 69% 0.300 67% 0.244
Female 187 (47) 3.63 3 3.67 2 64% 62%
Patient type
Adult medical 165 (41) 4.65 4 < 0.001 4.64 4 < 0.001 79% < 0.001 77% < 0.001
Adult surgical 105 (26) 3.31 3 3.35 2 69% 70%
Pediatric 130 (33) 2.47 1 2.74 2 48% 46%
Oncology status
Cancer
diagnosed
or
suspected
102 (25.5) 4.82 5 < 0.001 4.65 4 0.001 71% 0.283 68% 0.516
No cancer
diagnosis
308 (74.5) 3.17 2 3.36 2 65% 64%
HIV status
HIV-positive 48 (12) 4.46 3 0.049 4.50 4 0.074 81% 0.020 79% 0.030
HIV-negative 351 (88) 3.48 3 3.58 2 64% 63%
Pain medicine prescribed?
Yes 262 (65) 4.2 3 < 0.001 4.26 4 < 0.001 - -
No 138 (35) 2.44 1 2.60 2 - -
Strongest pain medicine prescribed
None 138 (35) 2.43 1 < 0.001 2.59 2 < 0.001 - -
Nonopioid 156 (39) 3.64 3 3.72 2 - -
Weak opioid 54 (14) 4.89 4 4.89 4 - -
Strong opioid 52 (13) 5.15 5 5.23 5 - -
Pain medicine given in past six hours?
Yes 108 (27) 4.29 4 0.006 4.41 4 0.005 33% < 0.001 31% < 0.001
No 292 (73) 3.33 3 3.42 2 78% 78%
All pain medicine given as prescribed?
Yes 92 (35) 3.85 3 0.201 3.93 4 0.221 46% < 0.001 46% < 0.001
No 170 (65) 4.39 3 4.44 4 74% 73%
Described inthe table are the demographics of study participants, including age,gender, patient category, cancerstatus,and HIV status. Meanand
median FPS-Rand NRS ratings are shownfor eachsubgroup, as wellasp-values.PainManagement Index (PMI) scores calculated using the NRS and
FPS-Rratingsareshownforeachpatientsubgroup.Descriptionsareshownofwhetherpainmedicinewasprescribed,thestrengthofthestrongestpain
medicine prescribed, whether the patient received pain medicine in the past six hours, and whether analgesics were administered as prescribed.
FPS-R, Faces Pain Scale–Revised; NRS, Numerical Rating Scale; PMI, Pain Management Index.
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Spearman correlation coefficients were calculated to assess
convergent validity between patient scores on the NRS and
the FPS-R. A correlation coefficient of between 0.50 and 0.75
was taken to show a moderate relationship and one of be-
tween 0.76 and 1.00 was taken to show a very good or excel-
lent relationship. For binary patient characteristic variables, the
Wilcoxon rank sum test was used to determine differences in
NRS and FPS-R ratings based on those patient characteristics.
The Kruskal-Wallis test was used for patient characteristics that
had more than two variable categories.
Using previously established definitions with minor ad-
justments for greater accuracy in our population, a PMI score
was calculated for each subject in order to assess adequacy of
analgesics.35 The PMI compares the patient’s pain rating to
prescribed analgesics to determine whether a patient’s pain is
adequately treated. The PMI is considered a conservative
measure of pain because it does not account for analgesic dos-
ing, which may not be sufficient for the patient’s pain.35,36 We
made two modifications to the PMI as originally described by
Cleeland and colleagues. First, we did not use the ‘‘worst pain’’
rating on the Brief Pain Inventory (BPI) but rather each patient’s
current pain rating on the NRS or FPS-R to determine the pa-
tient’s pain score. Second, rather than using the strongest pain
medicine prescribed to calculate the Analgesic Score, we used
the strongest analgesic received in the past six hours, since many
prescribed analgesics are never actually given to the patient in
this setting. Table 1 describes how the PMI was scored. A
negative PMI score indicated inadequate analgesic potency.
The v2 test was used to determine if there were significant
differences in PMI, pain medicine prescribing, or analgesia
administration based on patient characteristics. For all tests,
p-values < 0.05 were considered significant.
Results
We evaluated 400 hospitalized patients, ranging in age
from 5 to 88 years old (see Table 2). Of the participants, 47%
were female, 11% were HIV-positive, and 20% had a cancer
diagnosis. The two different pain scales utilized in this study,
the NRS and FPS-R, showed good concordance in assessing
point prevalence of pain. According to the NRS, 49% of pa-
tients had mild pain and 32% of patients had moderate to
severe pain. On the FPS-R, 51% of patients had mild pain and
28% of patients had moderate to severe pain. The average
pain rating on the NRS was 3.59 (standard deviation 3.29),
while the average pain rating on the FPS-R was 3.69 (standard
deviation 3.16) (see Figures 1 and 2). The convergent validity
between these two scales in our sample was 0.94.
The correlates of pain identified in this study included
increasing age, positive HIV status, and diagnosed or sus-
pected cancer. There was an association between the
strength of pain medicine prescribed and patients’ pain
ratings ( p < 0.001). There was no association between a pa-
tient’s pain rating on the FPS-R or NRS and gender, surgery
in the past 48 hours, or whether pain medicines were ad-
ministered as prescribed.
FIG. 1. Faces Pain Scale-Revised (FPS-R) responses. The percentage of patients choosing each response on the Faces Pain
Scale-Revised is shown above.28 (This figure has been reproduced with permission of the International Association for the
Study of Pain [IASP]).
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Pain medicine had been prescribed to 66% of participants at
some point during their hospitalization. Of all participants,
54.5% had been prescribed nonopioids, 17% had been pre-
scribed weak opioids, and 14% had been prescribed strong
opioids (see Table 3). Only 35% of subjects had received their
pain medicines as prescribed in the last 72 hours, while 27% of
all participants had received pain medicine within 6 hours
prior to being surveyed.
Surgical patients were much more likely to have been
prescribed analgesics and also to have been prescribed
stronger pain medicines than adult medical or pediatric pa-
tients ( p< 0.001) (see Table 4). Adult patients as a group were
more likely than pediatric patients to be prescribed pain
medicines (approaching significance at p = 0.050) and to be
prescribed stronger pain medicines ( p= 0.001).
The average PMI score calculated from each subject’s NRS
rating was - 1.0. The average PMI score calculated from each
subject’s FPS-R rating was - 0.9. A majority of patients (65%
on the FPS-R PMI and 66% on the NRS PMI) had undertreated
pain as indicated by a negative score on the PMI. HIV-positive
patients and adult patients were more likely to have under-
treated pain than HIV-negative patients and pediatric pa-
tients, respectively. Patients whose pain medicines were not
all given as prescribed were more likely to have undertreated
pain than those whose pain medicines were given as pre-
scribed ( p< 0.001). There was no association between under-
treatment of pain and gender, cancer status, chronic medical
problems, or surgery in the past 48 hours.
Discussion
This study is the first to describe the prevalence, intensity,
and treatment of pain in a general hospitalized patient pop-
ulation in East Africa. We have demonstrated that hospital-
ized patients in western Kenya experience a significant
amount of pain, with 80.5% of patients endorsing a nonzero
level of pain and 30.0% of patients reporting moderate to
FIG. 2. Numerical Rating Scale (NRS) responses. The percentage of patients choosing each response on the NRS is shown
above.
Table 3. Pain Medicines Prescribed
Analgesic prescribed Number (%)a
Nonopioids
Aspirin 5 (1.0)
Diclofenac 58 (14.5)
Ibuprofen 21 (5.0)
Paracetamolb 122 (30.5)
Buscopan 12 (3.0)
Total 218 (54.5)
Weak opioids
Dihydrocodeine 7 (2.0)
Tramadol 62 (15.5)
Total 69 (17.0)
Strong opioids
Pethidinec 24 (6.0)
Morphine 32 (8.0)
Total 56 (14.0)
This table shows the types of analgesics prescribed to hospitalized
patients in our study and the number of patients who had been
prescribed each analgesic.
aPercent of total sample (n = 400); many patients were prescribed
more than one pain medicine.
bAcetaminophen.
cMeperidine.
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severe pain (averaged across the NRS and FPS-R ratings).
There was a strong correlation between the NRS and the FPS-
R, further validating the use of these single-item pain scales in
this Kiswahili-speaking population.
The point prevalence of pain described in our study (80.5%)
is within the range of that found in other studies in SSA.9–17, 37
It is clear from prior data that pain is a considerable burden on
HIV-positive, cancer, and end-stage patients. This study now
establishes that hospitalized patients also carry a significant
amount of pain. These results help move the conversation
forward in SSA regarding pain management as a priority that
should be addressed not only in limited populations, but ra-
ther as a clinical skill with which all health practitioners
should be facile.
Similarly, the correlates of pain described here are in con-
cordance with those found in other studies, including in-
creasing age and medical comorbidities (in our case, HIV and
cancer).18,19 Unlike Harding and colleagues, we did not find
that female gender was correlated with symptom burden.20
This difference may rest in the fact that we investigated cor-
relates of pain only, while Harding and colleagues investi-
gated correlates of physical burden as a whole, including but
not limited to pain. Another possibility may be that Harding
and colleagues studied HIV patients attending palliative care
services, while the current research examined hospitalized
patients regardless of disease process.
Patients who were in greater pain were more likely to be
prescribed pain medication, to be prescribed analgesics of
stronger potency, and to have received pain medication
within the previous six hours, indicating an appropriate cor-
relation between pain intensity and treatment even when
management of pain was not achieved.
One of the most striking results of our study was that over
half of patients had undertreated pain as indicated by nega-
tive PMI scores. While analgesics—mostly nonopioids—are
prescribed to most patients, patients in this setting often do
not receive their pain medicines as prescribed. We believe that
potential reasons for undertreatment in our setting include
frequent and prolonged stock-outs of pain medications
(ranging from paracetamol to morphine); pain medicines not
being given as prescribed (due to staff shortages, system
failures making it easy to overlook giving medications at the
correct time, and other factors); and underprescribing by cli-
nicians.7,8 Addressing these barriers will require solutions to
be explored at several levels. At the state level it may help to
develop fail-safe supply chains to ensure government hospi-
tals always have essential medicines at affordable prices and
to clarify laws surrounding the proper use of opioids.2,41 At
the training level, clinicians must be educated in the appro-
priate use of analgesics and gain greater comfort in employing
these drugs.7,8 At the health care delivery level, patients
should be allowed the opportunity to communicate their pain
through routine pain assessment, and medication dispensing
systems should be improved.42
Our study had several limitations. First, we measured pain
at only one point in time. A patient’s experience of pain is not
a static phenomenon, and thus more comprehensive tools
such as the Brief Pain Inventory (BPI) and the African Pal-
liative Care Association (APCA) African Palliative Outcome
Scale are useful in generating a more complete symptom
history.43 However, the single-item pain scales employed in
our study are extremely quick to administer, since they only
ask one question and thus are more likely to be implemented
in our clinical setting. In addition, cross-sectional data on the
point prevalence of pain in this population of inpatients is an
important starting point. Previous studies have demonstrated
that single-item pain scales like the NRS are easily im-
plemented, well-accepted by patients, and useful to clini-
cians.44 Secondly, we made two modifications to the PMI. We
did not use the ‘‘worst pain’’ rating on the BPI but rather each
patient’s current pain rating on the NRS or FPS-R. If anything,
this gives a more conservative PMI score and underestimates
the proportion of patients whose pain is not adequately
treated. Also, rather than using the strongest pain medicine
prescribed to calculate the PMI, we used the strongest pain
medicine given within the past six hours. In our setting, so
many of the prescribed medicines were not given as pre-
scribed (due to stock-outs or other reasons) that calculating
Table 4. Analgesic Data
Demographic
variable
Pain medicines
prescribed (%) p-value
Pain medicines
given in
past
6 hours (%) p-value
Strongest
analgesic
prescribed (mean
Analgesic Score) p-value
All given as
prescribed
(%) p-value
Gender
Male 62 0.083 26 0.571 1.03 0.458 41 0.038
Female 70 28 1.07 29
Patient type
Adult medical 60 < 0.001 27 0.191 0.98 < 0.001 32 0.464
Adult surgical 83 21 1.44 33
Pediatric 59 32 0.83 41
HIV status
HIV-positive 58 0.260 21 0.318 0.92 0.364 43 0.348
HIV-negative 67 28 1.07 34
Oncology status
Cancer diagnosed or suspected 61 0.295 25 0.512 1.17 0.499 18 0.001
No cancer diagnosis 67 28 1.01 41
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the PMI from prescribed rather than administered analgesics
would have greatly overestimated the amount of pain treat-
ment each patient received. Lastly, we intentionally sampled a
heterogeneous patient population, in contrast with prior studies
that largely focused on cancer or HIV/AIDS patients. We be-
lieve that broadening the evidence base on pain assessment and
management in SSA to a wider population will benefit more
patients as our results are applied in clinical practice.
Our findings demonstrate that hospitalized patients in
western Kenya experience considerable amounts of pain,
much of it undertreated. It is our hope that these results
stimulate increasing awareness regarding patients’ pain and
encourage substantive clinician training in pain assessment
and management. The FPS-R and the NRS were easily un-
derstood and well accepted by participants and should be
implemented for daily use in the inpatient setting in order to
gauge patients’ pain and response to pain treatment. SSA al-
ready carries a great burden of disease; it does not also need to
carry a disproportionate burden of treatable pain.
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